A recent trial of dermoscopy and digital monitoring in Australian general practice found that the combination of these techniques can increase the sensitivity of GPs for the diagnosis of melanoma, and significantly reduce the proportion of benign lesions excised [ 17 ]. MD, University of Cambridge; In August , Astron Clinica Ltd was taken over by Biocompatibles International plc, which now holds these trademarks. British Journal of Dermatology. MoleMate, a non-invasive and pain-free melanoma screening device, will enable General Practitioners and skin specialists to scan and evaluate suspicious lesions within seconds and make instant clinical decisions ‘on the spot’. How GP practices can take the front line in the war against melanoma MoleMate, a non-invasive and pain-free melanoma screening device, will enable General Practitioners and skin specialists to scan and evaluate suspicious lesions within seconds and make instant clinical decisions ‘on the spot’. The patient or practitioner describes a pigmented lesion, although the lesion need not be the presenting symptom Participant type Patient Age group Adult Gender Both Target number of participants 1, participants from 15 general practices Participant exclusion criteria 1.
|Date Added:||27 December 2013|
|File Size:||50.73 Mb|
|Operating Systems:||Windows NT/2000/XP/2003/2003/7/8/10 MacOS 10/X|
|Price:||Free* [*Free Regsitration Required]|
Instant Mole screening with MoleMate from Astron Clinica | GPonline
All participants will be asked molematf complete an exit questionnaire within one week of their appointment and a follow-up questionnaire after 3 months. Provided by University of Western Australia.
Your message to the editors. The MoleMate system is said to be easier to learn than dermoscopy and predicts melanoma based on images of the epidermal and dermal melanin and vasculature, and the collagen content of the lesion.
You can be assured our editors closely monitor every feedback sent and will take appropriate actions. We decided to develop a new system specifically for GP practices that would give them access to the same technology that many dermatologists were using to scan suspicious moles so that they can offer a screening service in situ.
Designing and evaluating complex interventions to improve health care. In clinical practice, an expert opinion is considered the practical ‘standard’ of whether or not a pigmented lesion is ‘clinically significant’ in requiring monitoring or biopsy.
The MoleMate™ UK Trial: The management of suspicious pigmented lesions in primary care
The definition of ‘appropriateness of referral’ is whether the referred lesion is deemed ‘clinically significant’ by a dermatologist in a skin cancer clinic and is therefore either biopsied or monitored. GPs need to be able to reassure those with benign lesions and rapidly refer those with suspicious lesions. British Journal of Dermatology. Sensitivity, specificity and other study proportions of lesions will be analysed using the same approach as for the primary outcome measure. The patient or practitioner describes a pigmented lesion, although the lesion need not be the presenting symptom.
Media enquiries Lucy Saunders: Our pilot study confirmed projected recruitment rates participants per practice per month and referral rates approximately 2 referrals per practice per month.
Discussion This trial is designed to estimate the effect of the MoleMate intervention, compared with current best practice, on the management of suspicious pigmented lesions in general practice, as reflected in the appropriateness PPV of referrals to a skin cancer clinic.
Home News Education Practice About. Open in a separate window. We will therefore examine potential contamination effects by comparing the appropriateness and volume of referral between groups for the first ten MoleMate consultations of each Lead Clinician’s data collection when contamination would be minimal ‘naive period’with the remaining consultations ‘potentially contaminated period’. In conclusion, this is the first randomised controlled trial in general practice of a decision aid using SIAscopy for the assessment of pigmented skin lesions.
Molemae outcome measures 1. Other risk factors include genetic predisposition reflected in the phenotypic features of multiple moles, fair complexion, sunburn-susceptible skin types, and family history.
Shave biopsy is a safe and acceptable method for initial evaluation of melanoma May 23, Twenty-five practitioners worked through the MoleMate training program: Results and Publications Publication and dissemination plan Not provided at time of registration Intention to publish date Participant level data Not provided at time of registration Basic results scientific Publication list 1.
New MEDX SIMSYS-MoleMate Diagnostic tool For Sale – DOTmed Listing #
Abstract Background Suspicious pigmented lesions are a common presenting problem in general practice consultations; while the majority are benign a small minority are melanomas.
Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. molemqte
EH contributed to the finalisation of the study design following the pilot phase. Evaluation of the U.
Accuracy of Molemae for pigmented skin lesions encountered in primary care: The transformation rate of moles melanocytic nevi into cutaneous melanoma: What are the consequences? SIAscopy is an innovative technology that uses a non-invasive multispectral scanning technique to produce images of the light-absorbing chromaphores haemoglobin, melanin and collagen, in the epidermis and papillary dermis.